Search 

RiverVest Venture Partners is a venture capital firm that was founded in 2000 and is based in St. Louis, Missouri with additional office in Cleveland, Ohio. The firm currently has managed over $208 million of total assets. RiverVest has raised two investment funds with total committed capital of $165 million since inception. The recent fund closed at $75 million. RiverVest typically makes equity investments into global companies, and has no specific geographic preferences. The firm will consider making investments at all the stages, and focuses on investments in seed, early-stage and select later-stage companies. The typical investment size is around $6 million, though the firm can invest more or less, depending on the opportunity. 

RiverVest is extremely opportunistic when it comes to investments in the life sciences space; with that being said RiverVests specified sectors and sub sectors of interest may or may not be an area in which RiverVest is currently looking to allocate capital to. The firm invests in companies in the biotech therapeutics and diagnostics, as well the medical technology space. 

Some of the firms investments have included companies developing biotech therapeutics and diagnostics targeting diseases of the blood and blood forming organs, neoplasms, cancer, and oncology, skin and subcutaneous tissue, cardiovascular diseases, diseases of the ear, and infectious diseases. The firm has also invested in companies developing anti-body based therapeutics. The firm has also invested in firms developing medical technologies such as therapeutic radiation devices, active implantable devices, non active implantable devices, hospital hardware, and imaging devices.

Seroba Kernel is a venture capital firm based in Dublin, Ireland, with representatives in the United Kingdom. The firm has approximately €100M AUM and focuses solely on the life sciences. The firm has 2 funds and plans to raise a third fund in the near future. The firm typically allocates between €5-7M of equity over the life of the investment. The firm primarily invests in companies that are based in Ireland and Europe. Exceptional opportunities in North America will also be considered. The firm is actively seeking new investment opportunities.

Shire is an Irish-headquartered global specialty biopharmaceutical company. Originating in the United Kingdom with a large operational base in the United States, its brands and products include Vyvanse, Adderall XR, Intuniv, Lialda, Pentasa, Fosrenol, Replagal, Elaprase, VPRIV, Firazyr and Dermagraft. 

Shire is currently interested in several therapeutic areas for business development opportunities. The company is most interested in the following products: rare disease therapeutics, pre-clinical to on the market; neuroscience therapeutics, on the market; gastrointestinal, on the market; ophthalmology, post proof-of-concept; and hematology; post proof-of-concept.

Sofia Angel Group is a group of angel investors based in Minneapolis, Minnesota. The group solely focuses on investing in women-led businesses where women are the founders, or women are on the senior management team. Sofia Angel Group does not have a specific timeframe to make an investment, however would make an allocation by the end of 2013 if a compelling opportunity is identified. The group typically invests around $100,000 per company, however has the ability to invest up to $3 million through co-investments from the group’s members.

Rapid Development of Injection Molded Medical Devices
From Concept Through Transfer-to-Manufacturing

Symbient specializes in engineering research and development, prototyping and design-for-manufacturing of innovative medical devices that use injection molded components. Our highly experienced team consists of mechanical and biomedical engineers, industrial designers, machinists and molding technicians. They leverage our in-house rapid prototyping, and prototype tooling fabrication and injection molding to create proven, manufacturable designs with unmatched speed, efficiency and precision. These designs make up our deep portfolio of over 300 successful devices that have collectively generated hundreds of millions of dollars. They include FDA Class I, II and III devices, developed under our ISO 13485 certified quality management system.

Our Services Include:

• Concept Development
• Development Engineering
• Design-for-Manufacturing
• Industrial Design
• Project Rescue
• Design Control per IOS 13485
• Finite Element Analysis (FEA)
• Design Verification Testing
• Test Method Development
• Transfer to Manufacturing

Our In-House Capabilities and Expertise Include:

• Stereolithography (SLA) Prototyping
• CNC Machining / Fabrication
• Prototype Mold Fabrication
• Prototype Injection Molding of Devices for Testing, Trials and Studies
• Liquid Injection Molded (LIM) Silicone Prototype Molding
• Product Reliability Testing
• Plastics Assembly Expertise: Ultrasonic and Laser Welding, Heat Sealing, Pressure Sensitive Adhesives, Swaging, Snap Fits, Press Fits, Interlocks.
• Speed: Prototype Molds in as little as 1 week and Modifications in as little as 1 Day
• Material Selection Expertise, Research and Testing to Ensure All Product Requirements Are Met.

Our Portfolio Includes:

• Diagnostics / Molecular Diagnostics
• Sample collection / preparation
• Life Sciences / Microfluidics
• OTC Consumer products
• Respiratory
• Surgical devices and clinical tools
• Drug Delivery

Syncona Partners, founded in 2012, is an evergreen investment firm based in London, UK. The firm is an independent subsidiary of the Wellcome Trust who invested the initial £200m capitalization. The firm is mandated to invest in companies with the potential to make major breakthroughs in healthcare. The investment size will usually range from £1M – £20M per company. The firm seeks to create sustainable, profitable businesses, to support them with capital over the long term, for the benefit of patients, and to hold an ownership position to create value for the Wellcome Trust. The firm is actively screening new investment opportunities.

Founded in 1997, Tech Coast Angels is the largest angel investor group in the United States. Its members provide funding and guidance to more early-stage high-growth companies in Southern California than any other investment group. TCA members invest in companies in a wide range of industries including life sciences, biotech and health IT. TCA has more than 325 members including its venture capital affiliates in five networks in Los Angeles Orange County San Diego Westlake/Santa Barbara and the Inland Empire. The organization will finance on an opportunistic basis as long as substantial disruptive market opportunities exists. The firm has historically invested in Biotech Therapeutics & Diagnostics, Biotechnology R&D Services, Biotechnology Other, Medical Technology companies with sub sectors of Anti-Infectives, Bioinformatics, CRO (Contract Research Organization), Diagnostic Instrumentation, Diagnostic Services, Drug Delivery, Food, Industrial Biotechnology, Small Molecules, Small Molecule Therapeutics, Wound Care and indications including Diseases of the Nervous System, Infectious and Parasitic Diseases, Neoplasms/Cancer/Oncology, Respiratory.

Websites:
www.greenwingsbiomedical.com
techcoastangels.com

Twin Cities Angels is an angel group that was founded in 2006 that is based in Minnesota. The group has raised two funds that are The Twin Cities Angels Fund I and II. The second fund is currently looking to invest in emerging companies. The group typically provides seed and venture capital ranging from $ 25.000 to $2 million to life science companies. The group plans to invest in 4 to 6 companies per year. Twin Cities Angels seeks to invest in companies based in the Twin Cities Area of Minneapolis/St. Paul, the state of Minnesota and within a reasonable distance, such as Western Wisconsin, Northern Iowa, and Eastern Dakotas.

Vital Venture Capital, founded in 2007, is a venture capital firm with offices in: Simsbury, CT; Bethesda, MD; Philadelphia, PA; Naples, FL; and Lincolnshire, IL. The firm focuses on B2B, SaaS software, medical devices, and diagnostics. The firm seeks opportunities that provide some degree of investment loss protection through strong intellectual property. The firm’s target investment size is $1-3M for each portfolio company spread over 1-3 rounds. The firm invests in companies that are based in the US. The firm is actively seeking new investment opportunities.

Volcano Capital is a family office/venture capital firm based in New York. The firm manages an evergreen fund that operates free from the constraints of traditional venture capital funds. The firm seeks to make seed, venture, and growth equity investments in early to mid-stage medical device companies, but will also consider secured debt to help revenue generating companies with short term cash flow issues. The firm will also consider pre-seed investments. The firm can allocate anywhere from $1M to $10M per company, but generally allocates around $8M. The firm typically does 3 rounds of financing with an initial investment of around $3M. The firm is geographically agnostic, but highly prefers to invest in companies that are based in the US. The firm seeks to make about 3-4 allocations in the next 6-9 months.

Volcano Capital is currently looking for medical device companies with a strong emphasis on products with a 510(k) regulatory pathway. In terms of subsectors, the firm is looking for products specifically in the areas of interventional radiology and cardiology, spine/orthopedics and minimally invasive surgery. The firm is generally opportunistic in terms of indication.